Effect of Dose Modifications on Response to Duvelisib in Patients With Relapsed/refractory Cll/sll in the Duo Trial
Year: 2019
Type: article
Abstract: Conclusions: DUV monotherapy had a manageable safety profile and demonstrated significantly improved clinical outcomes over OFA in CLL/SLL pts who had received ≥2 prior therapies, a population in need of additional targeted therapies.
Source: Hematological Oncology
DOI: 10.1002/hon.30_2630
Institutions: Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Sarah Cannon, Columbia University Irving Medical Center, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, University of Debrecen, Institut Bergonié, Hospital Clínic de Barcelona, Flinders University, Flinders Medical Centre, The University of Melbourne, Peter MacCallum Cancer Centre, St Vincent's Hospital Melbourne, Ghent University Hospital, Vall d'Hebron Hospital Universitari, Dana-Farber Cancer Institute, Medical University of Vienna, Hôpital Avicenne, Laboratoire d'hématologie, Verastem (United States), University Hospital Ulm
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Bristol-Myers Squibb, Pfizer, AstraZeneca, Gilead Sciences, Teva Pharmaceutical Industries, Celgene, Karyopharm Therapeutics, TG Therapeutics, Sunesis, Agios Pharmaceuticals, Constellation Pharmaceuticals, Unum Therapeutics, BeiGene, Incyte, Calithera Biosciences, MorphoSys, Genentech, Kite Pharma, Pharmacyclics, Juno Therapeutics, Cilag
OpenAlex ID: W2951800991